SOURCE: MorphoSys AG

April 06, 2011 10:08 ET

Announcement of the Convening of the General Meeting in Munich/Germany on 19/05/2011 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution

MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - April 6, 2011) -

MorphoSys AG /

Announcement of the Convening of the General Meeting in Munich/Germany on 19/05/2011 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

MorphoSys AG
Martinsried/Planegg
Securities' code numbers: 663200 and A1H303
ISIN:DE0006632003 and DE000A1H3036

Invitation to the Annual Shareholders' Meeting 2011

We hereby invite the shareholders of our Company to the Annual Shareholders' Meeting which is taking place on Thursday, May 19, 2011 at 10.00 a.m., in the Conference Centre Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636 Munich.

Agenda

1. Presentation of the confirmed annual financial statements as of December 31, 2010, the management report together with the consolidated financial statements, the consolidated management report and the report of the Supervisory Board for the business year 2010 and the statement of the Board of Management to the items pursuant to § § 289 para. 4, 315 para. 4 HGB

2. Formal approval on behalf of the Board of Management

3. Formal approval on behalf of the Supervisory Board

4. Appointment of the auditors for the business year 2011

5. New Election to the Supervisory Board

6. Resolution on the Approval of the Remuneration Scheme of Members of the Board of Management

7. Resolution on the Authorization to purchase and use Treasury Stock and on the Exclusion of Subscription Rights

8. Creation of a new Conditional Capital 2011-I, authorization on behalf of the Board of Management to issue option and/or convertible bonds, exclusion of Subscription Rights; amendment of the Articles

9. Compensation of the Supervisory Board by Secondary Payments of the Company, Amendment of the Articles

Please find the full text of the announcement here: www.morphosys.com/agm

About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM- CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/

--- End of Message ---

MorphoSys AG

Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP; Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Bayerische Börse München, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in Frankfurter Wertpapierbörse;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1503984]

Contact Information

  • For more information, please contact:

    MorphoSys AG
    Dr. Claudia Gutjahr-Loser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122

    Mario Brkulj
    Senior Manager Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-454

    Jessica Kulpi
    Specialist Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-332

    Email Contact